9
5.59
-0.20 (-3.45%)
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (US) | Bullish | Bearish |
Medical Devices (Global) | Bullish | Bearish | |
Stock | 908 Devices Inc. | Mixed | Bearish |
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific. |
|
Sector | Healthcare |
Industry | Medical Devices |
Investment Style | Small Value |
Ownership
Name | Date | Shares Held |
---|---|---|
Iron Triangle Partners Lp | 31 Dec 2023 | 1,284,947 |
Tao Capital Management Lp | 31 Dec 2023 | 568,981 |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
30 Apr 2024 | Announcement | 908 Devices Reports First Quarter 2024 Financial Results and Updates 2024 Revenue Outlook |
30 Apr 2024 | Announcement | 908 Devices Acquires RedWave Technology, Expanding its Forensics Product Offering |
23 Apr 2024 | Announcement | 908 Devices to Report First Quarter 2024 Financial Results on April 30, 2024 |
12 Mar 2024 | Announcement | 908 Devices Trace Chemical Identification Technology Adopted by European Agencies |
05 Mar 2024 | Announcement | 908 Devices Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Revenue Outlook |
29 Feb 2024 | Announcement | 908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares’ Fully Integrated Cell Therapy Manufacturing Platform |
22 Feb 2024 | Announcement | 908 Devices to Participate in Upcoming Investor Conferences |
20 Feb 2024 | Announcement | 908 Devices to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 |
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |